The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy
Medical Oncology · 15.07.2024 · 41 (8)
DOI: 10.1007/s12032-024-02435-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, online erschienen am 15.07.2024. Verfasst von Chou-Yi Hsu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Chia Nan University of Pharmacy and Science, Tainan City, 71710, Taiwan. chouyihsu6@gmail.com. Hauptthemen laut MEDLINE: Neoplasms, Proprotein Convertase 9, Immunotherapy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 189 Literaturangaben.
Abstract (Originalsprache)
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a well-known regulator of cholesterol metabolism and cardiovascular diseases, has recently garnered attention for its emerging involvement in cancer biology. The multifunctional nature of PCSK9 extends beyond lipid regulation and encompasses a wide range of cellular processes that can influence cancer progression. Studies have revealed that PCSK9 can modulate signaling pathways, such as PI3K/Akt, MAPK, and Wnt/β-catenin, thereby influencing cellular proliferation, survival, and angiogenesis. Additionally, the interplay between PCSK9 and cholesterol homeostasis may impact membrane dynamics and cellular migration, further influencing tumor aggressiveness. The central role of the immune system in monitoring and controlling cancer is increasingly recognized. Recent research has demonstrated the ability of PCSK9 to modulate immune responses through interactions with immune cells and components of the tumor microenvironment. This includes effects on dendritic cell maturation, T cell activation, and cytokine production, suggesting a role in shaping antitumor immune responses. Moreover, the potential influence of PCSK9 on immune checkpoints such as PD1/PD-L1 lends an additional layer of complexity to its immunomodulatory functions. The growing interest in cancer immunotherapy has prompted exploration into the potential of targeting PCSK9 for therapeutic benefits. Preclinical studies have demonstrated synergistic effects between PCSK9 inhibitors and established immunotherapies, offering a novel avenue for combination treatments. The strategic manipulation of PCSK9 to enhance tumor immunity and improve therapeutic outcomes presents an exciting area for further investigations. Understanding the mechanisms by which PCSK9 influences cancer biology and immunity holds promise for the development of novel immunotherapeutic approaches. This review aims to provide a comprehensive analysis of the intricate connections between PCSK9, cancer pathogenesis, tumor immunity, and the potential implications for immunotherapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Chia Nan University of Pharmacy and Science, Tainan City, 71710, Taiwan. chouyihsu6@gmail.com.
- Thunderbird School of Global Management, Arizona State University Tempe Campus, Phoenix, AZ, 85004, USA. chouyihsu6@gmail.com.
- College of Education, University of Anbar, AL Qaim, Iraq.
- Department of Medical Laboratory Technology, Imam Jaafar AL-Sadiq University, Baghdad, Iraq.
- Department of Pathological Analyzes, College of Applied Sciences, University of Samarra, Samarra, Iraq.
- Department of Medical Laboratory Technics, Al-Noor University College, Nineveh, Iraq.
Zitieren
APA
Hsu, C. Y., Abdulrahim, M. N., Mustafa, M. A., Omar, T. M., Balto, F., Pineda, I., Khudair, T. T., Ubaid, M., & Ali, M. S. (2024). The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy. Medical Oncology, 41(8). https://doi.org/10.1007/s12032-024-02435-0
Vancouver
Hsu CY, Abdulrahim MN, Mustafa MA, Omar TM, Balto F, Pineda I, et al. The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy. Medical Oncology. 2024;41(8). doi:10.1007/s12032-024-02435-0
BibTeX
@article{Hsu2024,
author = {Hsu, Chou-Yi and Abdulrahim, Mustafa Nasrat and Mustafa, Mohammed Ahmed and Omar, Thabit Moath and Balto, Franklin and Pineda, Indira and Khudair, Teeba Thamer and Ubaid, Mohammed and Ali, Mohammed Shnain},
title = {The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy},
journal = {Medical Oncology},
year = {2024},
volume = {41},
number = {8},
doi = {10.1007/s12032-024-02435-0}
}
EUVIMED